| Effect of risedronate on the risk of hip fracture in elderly women MR McClung, P Geusens, PD Miller, H Zippel, WG Bensen, C Roux, ... New England journal of medicine 344 (5), 333-340, 2001 | 2566 | 2001 |
| Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial … SB Cohen, P Emery, MW Greenwald, M Dougados, RA Furie, ... Arthritis & Rheumatism 54 (9), 2793-2806, 2006 | 2280 | 2006 |
| A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease MJ Knapp, DS Knopman, PR Solomon, WW Pendlebury, CS Davis, ... Jama 271 (13), 985-991, 1994 | 1304 | 1994 |
| Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study S Cohen, RM Levy, M Keller, E Boling, RD Emkey, M Greenwald, TM Zizic, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1999 | 765 | 1999 |
| Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study JY Reginster, S Adami, P Lakatos, M Greenwald, JJ Stepan, SL Silverman, ... Annals of the rheumatic diseases 65 (5), 654-661, 2006 | 508 | 2006 |
| Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial CO Bingham III, RJ Looney, A Deodhar, N Halsey, M Greenwald, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2010 | 504 | 2010 |
| Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis PJ Mease, MC Genovese, MW Greenwald, CT Ritchlin, AD Beaulieu, ... New England Journal of Medicine 370 (24), 2295-2306, 2014 | 468 | 2014 |
| Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study M Dougados, D van der Heijde, YC Chen, M Greenwald, E Drescher, ... Annals of the rheumatic diseases 76 (1), 88-95, 2017 | 420 | 2017 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological … D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ... The Lancet 392 (10163), 2441-2451, 2018 | 379 | 2018 |
| A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis … SB Cohen, LW Moreland, JJ Cush, MW Greenwald, S Block, WJ Shergy, ... Annals of the rheumatic diseases 63 (9), 1062-1068, 2004 | 374 | 2004 |
| Two‐year results of once‐weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis Alendronate Once‐Weekly Study Group, R Rizzoli Journal of Bone and Mineral Research 17 (11), 1988-1996, 2002 | 310 | 2002 |
| Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies E Keystone, P Emery, CG Peterfy, PP Tak, S Cohen, MC Genovese, ... Annals of the rheumatic diseases 68 (2), 216-221, 2009 | 291 | 2009 |
| Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis American College of Rheumatology Task Force on Osteoporosis Guidelines Arthritis & Rheumatism 39 (11), 1791-1801, 1996 | 277 | 1996 |
| Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and … R Westhovens, PC Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, ... Annals of the rheumatic diseases 76 (6), 998-1008, 2017 | 263 | 2017 |
| Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose … A Kavanaugh, J Kremer, L Ponce, R Cseuz, OV Reshetko, ... Annals of the rheumatic diseases 76 (6), 1009-1019, 2017 | 253 | 2017 |
| Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind, placebo‐controlled … A Deodhar, D Poddubnyy, C Pacheco‐Tena, C Salvarani, ... Arthritis & rheumatology 71 (4), 599-611, 2019 | 245 | 2019 |
| Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial A Deodhar, D van der Heijde, LS Gensler, TH Kim, WP Maksymowych, ... The Lancet 395 (10217), 53-64, 2020 | 233 | 2020 |
| A phase II randomized study of subcutaneous ixekizumab, an anti–interleukin‐17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an … MC Genovese, M Greenwald, CS Cho, A Berman, L Jin, GS Cameron, ... Arthritis & rheumatology 66 (7), 1693-1704, 2014 | 219 | 2014 |
| Quality of life and disability in patients with treatment-failure gout MA Becker, HR Schumacher, KL Benjamin, P Gorevic, M Greenwald, ... The Journal of rheumatology 36 (5), 1041-1048, 2009 | 213 | 2009 |
| Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: results of a multicenter randomized, double‐blind, placebo‐controlled … MA Petri, PJ Mease, JT Merrill, RG Lahita, MJ Iannini, DE Yocum, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 179 | 2004 |
